Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria:

* Patient must have a histologically proven diagnosis of any EBV+ Hodgkin or non-Hodgkin lymphoma
* EBV positive will be defined as positive if LMP1 or 2 or EBER are positive. As long as EBV positive on a prior biopsy, EBV testing will not be required at the time of relapse. However, if EBV testing performed on a more recent biopsy and it is negative, that patient will be excluded.
* Patients must have had persistent, relapsed, or refractory disease to at least one prior regimen with plans to proceed to autologous stem cell transplant
* Patients must be in a complete remission at time of initial pheresis for vaccine preparation; complete remission will be determined using Cheson Criteria100
* There are no limits on the number of prior therapies allowed
* Able to give voluntary written informed consent
* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study therapy and for 3 months after vaccine #2.
* Male subject agrees to use an acceptable method for contraception for the duration of the study therapy and for 3 months after vaccine #2.
* Patients must be 18 years of age or older.
* ECOG performance status 0-2.

Exclusion Criteria

* An estimated or measured creatinine clearance of less than 30 ml/min.
* AST, ALT, total bilirubin \> 3 times the upper limit of normal
* Patients on chronic immunosuppressive therapy for any reason (other than chemotherapy for HL)
* Chronic systemic steroid therapy at doses greater than 10mg/day of prednisone or its equivalent.
* Female subject is pregnant or lactating. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result within 48 hours of enrollment. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
* Patient has received other investigational drugs for this disease within 14 days of enrollment
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
* Patients who are HIV positive AND have a CD4 count \<50
* Prior solid organ transplant or allogeneic stem cell transplant